XOMA
Open
$40.88
Prev. Close
$40.88
High
$41.00
Low
$40.80
Market Snapshot
$507.58M
27.4
-2.02
$28.49M
13
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
emptyResult
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Recently from Cashu
XOMA Reports Strong Q4 Results, Reinforces Position in Biotech Industry Growth
XOMA Royalty Corporation: Strengthening its Position in the Biotech Landscape XOMA Royalty Corporation (NASDAQ:XOMA) demonstrates robust growth and operational efficiency as it releases its fourth-qua…
Assessing XOMA Royalty: Growth Potential and Market Risks in Biotechnology
XOMA Royalty: Navigating Opportunities and Risks in Biotechnology XOMA Royalty, a key player in the biotechnology sector, garners significant attention from financial analysts who provide contrasting…
Analysts Split on XOMA Royalty’s Biotech Future: Opportunities and Risks Abound
XOMA Royalty Faces Divergent Analyst Perspectives Amid Biotech Developments XOMA Royalty (NASDAQ:XOMA) captures significant attention from industry analysts, reflecting a mix of optimism and caution r…
XOMA's Clinical Trial Setback: Challenges Ahead for Future Collaborations and Investor Confidence
XOMA Faces Clinical Setback: Implications for Future Collaborations XOMA Royalty Corporation finds itself at a critical juncture following the recent disappointing clinical trial results for Ersodetug…